Mr. Marasco will provide strategic direction to BioAgilytix’s global business development and marketing functions / teams to further expand worldwide adoption of the company’s premier bioanalytical services.
Cambridge Biomedical, a contract research organization based in the Cambridge area of Massachusetts, also specializes in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the heart of the world’s major biotech center, and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany.
BioAgilytix has received its Certificate of Registration from the Clinical Laboratory Improvement Amendments (CLIA) program regulated by the Centers for Medicare & Medicaid Services (CMS) for its U.S. facility in Durham, NC. The CLIA certificate confirms that BioAgilytix is now able to perform lab-developed tests in the diagnostic immunology specialty that are deemed “high complexity” and subject to CLIA oversight.
BioAgilytix has been named by Triangle Business Journal as a Fast 50 Award winner for 2019, marking the seventh time the organization has been recognized as one of the fastest growing privately held companies in the Triangle Park area.
Mr. Zajkowski brings more than 25 years of experience managing finance functions in private equity-sponsored and publicly-traded companies, including multiple healthcare and life sciences organizations.
BioAgilytix has been named to Inc. Magazine’s Inc. 5000 list of the fastest-growing private companies in America for 2019: its sixth appearance on the list in the last seven years.
BioAgilytix has completed the latest expansion of its Durham, NC campus, which serves as the company’s USA headquarters, with the opening of an additional 21,173 square foot building directly adjacent to its existing facility.
In this role, Mr. Blake will lead the development, assessment, and execution of critical IT strategies across BioAgilytix’s international operations to support the company’s continued growth and position as a technologically-advanced bioanalytical services provider.
BioAgilytix has announced that Corinna Fiorotti, Ph.D., has been promoted to Scientific Officer and Key Accounts Director for the company, and will take a leading role in developing and managing customer accounts throughout North America.
BioAgilytix has announced several promotions within its leadership team. PD Dr. Arno Kromminga has been promoted to Global Chief Scientific Officer, and will lead BioAgilytix’s global scientific strategy while also continuing to serve as the European Managing Director. Beth Heinz has been promoted to Vice President of Global Business Development and will continue her focus on cultivating and managing both strong client relationships and strategic partnerships worldwide.
Services
Platforms